Intelligent Bio Solutions Expands Forensic Drug Testing in Texas Through Strategic Partnership
Summary
Intelligent Bio Solutions Inc. (NASDAQ: INBS), in partnership with SMARTOX, a Texas-based leader in drug and alcohol screening services, has reported significant growth in the U.S. Forensic Use Only Market. The collaboration has led to the deployment of over 50 INBS Intelligent Fingerprinting Drug Screening Readers and the conduction of more than 7,000 tests, showcasing the increasing demand for INBS's innovative, non-invasive testing solution. This technology, which utilizes fingerprint sweat for drug detection, offers a more efficient and dignified alternative to traditional urine and saliva tests, particularly beneficial in corrections, rehabilitation, and drug court settings. INBS is also advancing towards FDA clearance for its codeine opiate test, with ambitions to penetrate the workplace drug testing market later this year.
For more details, visit the full article. Intelligent Bio Solutions Inc. is at the forefront of revolutionizing portable drug testing through its Intelligent Fingerprinting Drug Screening System, aiming to expand its applications beyond the current markets. The company's technology is designed for quick and hygienic drug screening, targeting substances like opiates, cocaine, methamphetamine, and cannabis, with results available in under ten minutes. This positions INBS as a potential game-changer for employers in safety-critical industries seeking reliable and efficient drug testing solutions.
Full Article
The collaboration between Intelligent Bio Solutions Inc. (NASDAQ: INBS) and SMARTOX, a Texas leader in drug and alcohol screening services, has catalyzed a notable expansion in the forensic drug testing market. With the deployment of more than 50 INBS Intelligent Fingerprinting Drug Screening Readers and the completion of over 7,000 tests, including 1,500 in 2024, this partnership underscores the escalating demand for innovative drug testing solutions. The INBS technology, which utilizes fingerprint sweat analysis, presents a rapid, non-invasive alternative to conventional urine and saliva tests, enhancing both efficiency and user dignity in testing scenarios such as corrections, rehabilitation, and drug courts.
This technological advancement is not only revolutionizing the way drug tests are conducted but also setting the stage for broader applications. INBS is actively pursuing FDA clearance for its codeine opiate test, with plans to venture into workplace drug testing later this year. The Intelligent Fingerprinting Drug Screening System, designed for portability, hygiene, and cost-effectiveness, screens for recent use of commonly abused substances, including opiates, cocaine, methamphetamine, and cannabis. Its ability to deliver results in under ten minutes represents a significant boon for employers in safety-critical industries, offering a swift and dignified testing method.
The partnership with SMARTOX not only validates the efficacy and reliability of INBS's technology but also signifies a critical milestone in the company's expansion within the U.S. forensic market. As INBS continues to innovate and navigate the regulatory landscape, its solutions are anticipated to address the pressing challenges of drug testing across various sectors. By providing a faster, more efficient, and less invasive alternative to traditional methods, INBS is poised to make a lasting impact on the industry, enhancing safety and compliance in workplaces and beyond.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 81005